WINTER PARK, FL (January, 2024) – In November 2022, the U.S. Food and Drug Administration (FDA) weighed the evidence for teplizumab to delay type 1 diabetes (T1D) in at-risk individuals, and the T1D community got a big win: Approved, under the brand name TzieldTM! Tzield (teplizumab-mzwv) is the first disease-modifying therapy for individuals at-risk for developing T1D. (At-risk means that they exhibited 2+ T1D-related autoantibodies–antibodies against one’s own self–and their blood glucose is starting to be abnormal, but they have not yet become insulin dependent.)
For the first time in history, there is an approved therapy that addresses the autoimmunity behind T1D–not just the symptoms that it causes in 1.4 million Americans.
The Northern Florida chapter of JDRF will continue this effort to push monumental research advances forward through their three annual walks this spring–April 20 in Tampa, April 28 in Orlando, and May 4 in Jacksonville.
Aiming to raise more than $1,273,000 in Northern Florida, the JDRF One Walk is the largest T1D event in the world that powers more research, enables more advocacy, and funds more support for those living with T1D. Individuals, families and corporations that join JDRF One Walk are a part of the lasting footprint that will continue to make history for the T1D community now, and for generations to come.
“We are excited to host families and friends in the T1D community across Northern Florida this year. It’s inspiring to see the passion and dedication from our teams and corporate sponsors to turn type one to type none. It’s because of them, that we are able to continue our mission to cure, prevent and treat T1D. We’ve never been closer to a cure than now, and we are excited to celebrate with our teams,” says Colleen Saca, Executive Director of JDRF Northern Florida.
Registration is now open, learn more: walk.jdrf.org.
JDRF gratefully acknowledges its local corporate partners that have already committed to our 2024 One Walks including Lilly Diabetes, Florida Blue, Firehouse Subs, Kemper, and AdventHealth for Children. For sponsorship opportunities, contact firstname.lastname@example.org.
Type 1 diabetes is an autoimmune disease in which a person’s pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body’s immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. While its causes are not yet entirely understood, scientists believe that both genetic factors and environmental triggers are involved. Its onset has nothing to do with diet or lifestyle. There is nothing you can do to prevent T1D, and—at present—nothing you can do to get rid of it.
JDRF is the leading global organization funding type 1 diabetes research. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested more than $2.8 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our six international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit jdrf.org.